Gejl et al. (2016) found that GLP-1RA liraglutide exhibited significant enhancements in cognitive function among patients with MCI and AD, as compared to the placebo group. Several basic researches (Talbot & Wang, 2014; Batista et al., 2019; Tai et al., 2018) found that GLP-1 receptor agonists possess the ability to effectively retard neurodegeneration in Alzheimer’s disease, potentially through their mechanism of attenuating neuroinflammation and reducing amyloid deposition. The gene discussed is GLP1R; the disease is Alzheimer disease.